Taysha Gene Therapies (TSHA) Cash from Operations (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Cash from Operations data on file, last reported at 40878000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 85.64% year-over-year to 40878000.0; the trailing twelve-month figure through Mar 2026 stood at 111948000.0 (down 34.15% YoY), and the FY2025 full-year result was 93090000.0, down 14.61% from the prior year.
• Cash from Operations fell to 40878000.0 in Q1 2026, from 26722000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 14712000.0 in Q4 2022 to a low of 40939000.0 in Q1 2022.
• A 5-year average of 22153000.0 and a median of 21504000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations soared 136.54% in 2022 and slumped 209.55% in 2023, its largest moves.
• Tracing TSHA's Cash from Operations over 5 years: stood at 14712000.0 in 2022, then tumbled by 209.55% to 16117000.0 in 2023, then slipped by 13.59% to 18308000.0 in 2024, then tumbled by 45.96% to 26722000.0 in 2025, then sank by 52.98% to 40878000.0 in 2026.
• Business Quant data shows TSHA's Cash from Operations at 40878000.0 in Q1 2026, 26722000.0 in Q4 2025, and 24166000.0 in Q3 2025.